A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival
Abstract Purpose To develop a prognostic test based on a single blood sample obtained at the time of uveal melanoma diagnosis. Methods 83 patients diagnosed with posterior uveal melanoma between 1996 and 2000 were included. Peripheral serum samples were obtained at diagnosis and kept at -80 °C until...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-03-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-023-10757-x |
| _version_ | 1797853750663053312 |
|---|---|
| author | Christina Herrspiegel Flavia Plastino Emma Lardner Stefan Seregard Pete A. Williams Helder André Gustav Stålhammar |
| author_facet | Christina Herrspiegel Flavia Plastino Emma Lardner Stefan Seregard Pete A. Williams Helder André Gustav Stålhammar |
| author_sort | Christina Herrspiegel |
| collection | DOAJ |
| description | Abstract Purpose To develop a prognostic test based on a single blood sample obtained at the time of uveal melanoma diagnosis. Methods 83 patients diagnosed with posterior uveal melanoma between 1996 and 2000 were included. Peripheral serum samples were obtained at diagnosis and kept at -80 °C until this analysis. Protein profiling of 84 cancer-related proteins was used to screen for potential biomarkers and a prognostic test that stratifies patients into metastatic risk categories was developed (serUM-Px) in a training cohort and then tested in a validation cohort. Results Low serum leptin levels and high osteopontin levels were found to identify patients with poor prognosis and were therefore selected for inclusion in the final test. In the validation cohort, patient sex and American Joint Committee on Cancer stages were similarly distributed between the low, intermediate, and high metastatic risk categories. With increasing metastatic risk category, patients had shorter metastasis-free- and overall survival, as well as greater cumulative incidence of uveal melanoma-related mortality in competing risk analysis (P = 0.007, 0.018 and 0.029, respectively). In multivariate Cox regression, serUM-Px was an independent predictor of metastasis with tumor size and patient sex as covariates (hazard ratio 3.2, 95% CI 1.5–6.9). Conclusions A prognostic test based on a single peripheral venous blood sample at the time of uveal melanoma diagnosis stratifies patients into low, intermediate, and high metastatic risk categories. Prospective validation will facilitate its clinical utility. |
| first_indexed | 2024-04-09T19:55:47Z |
| format | Article |
| id | doaj.art-dfb5ef89f6d14bec8ec1dc4e25f047dc |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-09T19:55:47Z |
| publishDate | 2023-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-dfb5ef89f6d14bec8ec1dc4e25f047dc2023-04-03T05:30:41ZengBMCBMC Cancer1471-24072023-03-0123111510.1186/s12885-023-10757-xA serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survivalChristina Herrspiegel0Flavia Plastino1Emma Lardner2Stefan Seregard3Pete A. Williams4Helder André5Gustav Stålhammar6St. Erik Eye HospitalDepartment of Clinical Neuroscience, Division of Eye and Vision, Karolinska InstitutetSt. Erik Eye HospitalSt. Erik Eye HospitalSt. Erik Eye HospitalDepartment of Clinical Neuroscience, Division of Eye and Vision, Karolinska InstitutetSt. Erik Eye HospitalAbstract Purpose To develop a prognostic test based on a single blood sample obtained at the time of uveal melanoma diagnosis. Methods 83 patients diagnosed with posterior uveal melanoma between 1996 and 2000 were included. Peripheral serum samples were obtained at diagnosis and kept at -80 °C until this analysis. Protein profiling of 84 cancer-related proteins was used to screen for potential biomarkers and a prognostic test that stratifies patients into metastatic risk categories was developed (serUM-Px) in a training cohort and then tested in a validation cohort. Results Low serum leptin levels and high osteopontin levels were found to identify patients with poor prognosis and were therefore selected for inclusion in the final test. In the validation cohort, patient sex and American Joint Committee on Cancer stages were similarly distributed between the low, intermediate, and high metastatic risk categories. With increasing metastatic risk category, patients had shorter metastasis-free- and overall survival, as well as greater cumulative incidence of uveal melanoma-related mortality in competing risk analysis (P = 0.007, 0.018 and 0.029, respectively). In multivariate Cox regression, serUM-Px was an independent predictor of metastasis with tumor size and patient sex as covariates (hazard ratio 3.2, 95% CI 1.5–6.9). Conclusions A prognostic test based on a single peripheral venous blood sample at the time of uveal melanoma diagnosis stratifies patients into low, intermediate, and high metastatic risk categories. Prospective validation will facilitate its clinical utility.https://doi.org/10.1186/s12885-023-10757-xUveal melanomaChoroidal melanomaLiquid biopsySerum sampleProteomePrognosis |
| spellingShingle | Christina Herrspiegel Flavia Plastino Emma Lardner Stefan Seregard Pete A. Williams Helder André Gustav Stålhammar A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival BMC Cancer Uveal melanoma Choroidal melanoma Liquid biopsy Serum sample Proteome Prognosis |
| title | A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival |
| title_full | A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival |
| title_fullStr | A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival |
| title_full_unstemmed | A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival |
| title_short | A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival |
| title_sort | serum protein signature at the time of uveal melanoma diagnosis predicts long term patient survival |
| topic | Uveal melanoma Choroidal melanoma Liquid biopsy Serum sample Proteome Prognosis |
| url | https://doi.org/10.1186/s12885-023-10757-x |
| work_keys_str_mv | AT christinaherrspiegel aserumproteinsignatureatthetimeofuvealmelanomadiagnosispredictslongtermpatientsurvival AT flaviaplastino aserumproteinsignatureatthetimeofuvealmelanomadiagnosispredictslongtermpatientsurvival AT emmalardner aserumproteinsignatureatthetimeofuvealmelanomadiagnosispredictslongtermpatientsurvival AT stefanseregard aserumproteinsignatureatthetimeofuvealmelanomadiagnosispredictslongtermpatientsurvival AT peteawilliams aserumproteinsignatureatthetimeofuvealmelanomadiagnosispredictslongtermpatientsurvival AT helderandre aserumproteinsignatureatthetimeofuvealmelanomadiagnosispredictslongtermpatientsurvival AT gustavstalhammar aserumproteinsignatureatthetimeofuvealmelanomadiagnosispredictslongtermpatientsurvival AT christinaherrspiegel serumproteinsignatureatthetimeofuvealmelanomadiagnosispredictslongtermpatientsurvival AT flaviaplastino serumproteinsignatureatthetimeofuvealmelanomadiagnosispredictslongtermpatientsurvival AT emmalardner serumproteinsignatureatthetimeofuvealmelanomadiagnosispredictslongtermpatientsurvival AT stefanseregard serumproteinsignatureatthetimeofuvealmelanomadiagnosispredictslongtermpatientsurvival AT peteawilliams serumproteinsignatureatthetimeofuvealmelanomadiagnosispredictslongtermpatientsurvival AT helderandre serumproteinsignatureatthetimeofuvealmelanomadiagnosispredictslongtermpatientsurvival AT gustavstalhammar serumproteinsignatureatthetimeofuvealmelanomadiagnosispredictslongtermpatientsurvival |